Clinical trial
A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 in Combination With Docetaxel (Taxotere™) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC).
NCT00494481 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 in Combination With Docetaxel (Taxotere™) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC).
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2006
- Completion date
- January 31, 2009
- Enrollment
- 64 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
advanced breast cancer